nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—ABCG2—Topotecan—ovarian cancer	0.166	0.27	CbGbCtD
Rabeprazole—ABCG2—Paclitaxel—ovarian cancer	0.082	0.133	CbGbCtD
Rabeprazole—ABCG2—Carboplatin—ovarian cancer	0.0772	0.126	CbGbCtD
Rabeprazole—ABCG2—Docetaxel—ovarian cancer	0.0593	0.0965	CbGbCtD
Rabeprazole—ABCG2—Doxorubicin—ovarian cancer	0.0442	0.0719	CbGbCtD
Rabeprazole—CYP2D6—Vinorelbine—ovarian cancer	0.0397	0.0645	CbGbCtD
Rabeprazole—CYP3A4—Topotecan—ovarian cancer	0.0358	0.0582	CbGbCtD
Rabeprazole—CYP2C9—Paclitaxel—ovarian cancer	0.0305	0.0496	CbGbCtD
Rabeprazole—CYP3A4—Vinorelbine—ovarian cancer	0.0252	0.041	CbGbCtD
Rabeprazole—CYP3A4—Paclitaxel—ovarian cancer	0.0177	0.0288	CbGbCtD
Rabeprazole—CYP2D6—Doxorubicin—ovarian cancer	0.015	0.0244	CbGbCtD
Rabeprazole—CYP3A4—Docetaxel—ovarian cancer	0.0128	0.0208	CbGbCtD
Rabeprazole—CYP3A4—Doxorubicin—ovarian cancer	0.00955	0.0155	CbGbCtD
Rabeprazole—Omeprazole—CYP1B1—ovarian cancer	0.00246	0.355	CrCbGaD
Rabeprazole—Lansoprazole—CYP1B1—ovarian cancer	0.00225	0.325	CrCbGaD
Rabeprazole—Pantoprazole—ABCB1—ovarian cancer	0.000867	0.125	CrCbGaD
Rabeprazole—Omeprazole—ABCB1—ovarian cancer	0.000707	0.102	CrCbGaD
Rabeprazole—Lansoprazole—ABCB1—ovarian cancer	0.000646	0.0932	CrCbGaD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000157	0.00335	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—ovarian cancer	0.000157	0.00335	CbGpPWpGaD
Rabeprazole—Pancreatitis—Doxorubicin—ovarian cancer	0.000157	0.000472	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000156	0.000472	CcSEcCtD
Rabeprazole—Weight decreased—Epirubicin—ovarian cancer	0.000156	0.000471	CcSEcCtD
Rabeprazole—Hyperglycaemia—Epirubicin—ovarian cancer	0.000156	0.00047	CcSEcCtD
Rabeprazole—Cough—Docetaxel—ovarian cancer	0.000156	0.000469	CcSEcCtD
Rabeprazole—Angina pectoris—Doxorubicin—ovarian cancer	0.000156	0.000469	CcSEcCtD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000155	0.00332	CbGpPWpGaD
Rabeprazole—Insomnia—Paclitaxel—ovarian cancer	0.000155	0.000468	CcSEcCtD
Rabeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000155	0.00331	CbGpPWpGaD
Rabeprazole—Pneumonia—Epirubicin—ovarian cancer	0.000155	0.000467	CcSEcCtD
Rabeprazole—Convulsion—Docetaxel—ovarian cancer	0.000154	0.000466	CcSEcCtD
Rabeprazole—Paraesthesia—Paclitaxel—ovarian cancer	0.000154	0.000465	CcSEcCtD
Rabeprazole—Hypertension—Docetaxel—ovarian cancer	0.000154	0.000464	CcSEcCtD
Rabeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.000154	0.00329	CbGpPWpGaD
Rabeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000154	0.00328	CbGpPWpGaD
Rabeprazole—Bronchitis—Doxorubicin—ovarian cancer	0.000154	0.000463	CcSEcCtD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000153	0.00327	CbGpPWpGaD
Rabeprazole—Dyspnoea—Paclitaxel—ovarian cancer	0.000153	0.000462	CcSEcCtD
Rabeprazole—Somnolence—Paclitaxel—ovarian cancer	0.000153	0.00046	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000153	0.00046	CcSEcCtD
Rabeprazole—Arthralgia—Docetaxel—ovarian cancer	0.000152	0.000458	CcSEcCtD
Rabeprazole—Chest pain—Docetaxel—ovarian cancer	0.000152	0.000458	CcSEcCtD
Rabeprazole—Myalgia—Docetaxel—ovarian cancer	0.000152	0.000458	CcSEcCtD
Rabeprazole—Pancytopenia—Doxorubicin—ovarian cancer	0.000152	0.000457	CcSEcCtD
Rabeprazole—Nausea—Vinorelbine—ovarian cancer	0.000152	0.000457	CcSEcCtD
Rabeprazole—Dyspepsia—Paclitaxel—ovarian cancer	0.000151	0.000456	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000151	0.000455	CcSEcCtD
Rabeprazole—Stomatitis—Epirubicin—ovarian cancer	0.00015	0.000452	CcSEcCtD
Rabeprazole—Jaundice—Epirubicin—ovarian cancer	0.00015	0.000452	CcSEcCtD
Rabeprazole—Urinary tract infection—Epirubicin—ovarian cancer	0.00015	0.000451	CcSEcCtD
Rabeprazole—Conjunctivitis—Epirubicin—ovarian cancer	0.00015	0.000451	CcSEcCtD
Rabeprazole—CYP1A2—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000149	0.00319	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.000149	0.00319	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000149	0.00319	CbGpPWpGaD
Rabeprazole—Dysuria—Doxorubicin—ovarian cancer	0.000149	0.00045	CcSEcCtD
Rabeprazole—Neutropenia—Doxorubicin—ovarian cancer	0.000149	0.00045	CcSEcCtD
Rabeprazole—Decreased appetite—Paclitaxel—ovarian cancer	0.000149	0.00045	CcSEcCtD
Rabeprazole—Dry mouth—Docetaxel—ovarian cancer	0.000148	0.000448	CcSEcCtD
Rabeprazole—Sweating—Epirubicin—ovarian cancer	0.000147	0.000445	CcSEcCtD
Rabeprazole—Pollakiuria—Doxorubicin—ovarian cancer	0.000147	0.000445	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000147	0.00315	CbGpPWpGaD
Rabeprazole—Pain—Paclitaxel—ovarian cancer	0.000147	0.000443	CcSEcCtD
Rabeprazole—Constipation—Paclitaxel—ovarian cancer	0.000147	0.000443	CcSEcCtD
Rabeprazole—Haematuria—Epirubicin—ovarian cancer	0.000147	0.000442	CcSEcCtD
Rabeprazole—Confusional state—Docetaxel—ovarian cancer	0.000147	0.000442	CcSEcCtD
Rabeprazole—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000146	0.00044	CcSEcCtD
Rabeprazole—Oedema—Docetaxel—ovarian cancer	0.000145	0.000439	CcSEcCtD
Rabeprazole—Anaphylactic shock—Docetaxel—ovarian cancer	0.000145	0.000439	CcSEcCtD
Rabeprazole—Weight increased—Doxorubicin—ovarian cancer	0.000145	0.000438	CcSEcCtD
Rabeprazole—Epistaxis—Epirubicin—ovarian cancer	0.000145	0.000438	CcSEcCtD
Rabeprazole—Weight decreased—Doxorubicin—ovarian cancer	0.000144	0.000436	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—ovarian cancer	0.000144	0.00309	CbGpPWpGaD
Rabeprazole—Sinusitis—Epirubicin—ovarian cancer	0.000144	0.000435	CcSEcCtD
Rabeprazole—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000144	0.000434	CcSEcCtD
Rabeprazole—Agranulocytosis—Epirubicin—ovarian cancer	0.000144	0.000433	CcSEcCtD
Rabeprazole—Pneumonia—Doxorubicin—ovarian cancer	0.000143	0.000432	CcSEcCtD
Rabeprazole—Shock—Docetaxel—ovarian cancer	0.000143	0.000432	CcSEcCtD
Rabeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000143	0.00305	CbGpPWpGaD
Rabeprazole—Thrombocytopenia—Docetaxel—ovarian cancer	0.000142	0.00043	CcSEcCtD
Rabeprazole—Tachycardia—Docetaxel—ovarian cancer	0.000142	0.000428	CcSEcCtD
Rabeprazole—Feeling abnormal—Paclitaxel—ovarian cancer	0.000141	0.000427	CcSEcCtD
Rabeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000141	0.00302	CbGpPWpGaD
Rabeprazole—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000141	0.000426	CcSEcCtD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000141	0.00301	CbGpPWpGaD
Rabeprazole—Bradycardia—Epirubicin—ovarian cancer	0.000141	0.000424	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	0.000141	0.003	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00014	0.000423	CcSEcCtD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.00014	0.00299	CbGpPWpGaD
Rabeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.00014	0.00298	CbGpPWpGaD
Rabeprazole—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00014	0.000421	CcSEcCtD
Rabeprazole—Stomatitis—Doxorubicin—ovarian cancer	0.000139	0.000419	CcSEcCtD
Rabeprazole—Jaundice—Doxorubicin—ovarian cancer	0.000139	0.000419	CcSEcCtD
Rabeprazole—Anorexia—Docetaxel—ovarian cancer	0.000139	0.000418	CcSEcCtD
Rabeprazole—Rhinitis—Epirubicin—ovarian cancer	0.000138	0.000418	CcSEcCtD
Rabeprazole—Conjunctivitis—Doxorubicin—ovarian cancer	0.000138	0.000417	CcSEcCtD
Rabeprazole—Urinary tract infection—Doxorubicin—ovarian cancer	0.000138	0.000417	CcSEcCtD
Rabeprazole—Hepatitis—Epirubicin—ovarian cancer	0.000138	0.000417	CcSEcCtD
Rabeprazole—Pharyngitis—Epirubicin—ovarian cancer	0.000137	0.000413	CcSEcCtD
Rabeprazole—Sweating—Doxorubicin—ovarian cancer	0.000136	0.000412	CcSEcCtD
Rabeprazole—Urinary tract disorder—Epirubicin—ovarian cancer	0.000136	0.000411	CcSEcCtD
Rabeprazole—Urticaria—Paclitaxel—ovarian cancer	0.000136	0.000411	CcSEcCtD
Rabeprazole—Oedema peripheral—Epirubicin—ovarian cancer	0.000136	0.00041	CcSEcCtD
Rabeprazole—Hypotension—Docetaxel—ovarian cancer	0.000136	0.00041	CcSEcCtD
Rabeprazole—Haematuria—Doxorubicin—ovarian cancer	0.000136	0.000409	CcSEcCtD
Rabeprazole—Body temperature increased—Paclitaxel—ovarian cancer	0.000136	0.000409	CcSEcCtD
Rabeprazole—Abdominal pain—Paclitaxel—ovarian cancer	0.000136	0.000409	CcSEcCtD
Rabeprazole—Urethral disorder—Epirubicin—ovarian cancer	0.000135	0.000408	CcSEcCtD
Rabeprazole—Epistaxis—Doxorubicin—ovarian cancer	0.000134	0.000405	CcSEcCtD
Rabeprazole—Sinusitis—Doxorubicin—ovarian cancer	0.000134	0.000403	CcSEcCtD
Rabeprazole—Visual impairment—Epirubicin—ovarian cancer	0.000133	0.000401	CcSEcCtD
Rabeprazole—Agranulocytosis—Doxorubicin—ovarian cancer	0.000133	0.000401	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000133	0.0004	CcSEcCtD
Rabeprazole—Insomnia—Docetaxel—ovarian cancer	0.000132	0.000397	CcSEcCtD
Rabeprazole—Paraesthesia—Docetaxel—ovarian cancer	0.000131	0.000394	CcSEcCtD
Rabeprazole—Erythema multiforme—Epirubicin—ovarian cancer	0.000131	0.000394	CcSEcCtD
Rabeprazole—Bradycardia—Doxorubicin—ovarian cancer	0.00013	0.000392	CcSEcCtD
Rabeprazole—Dyspnoea—Docetaxel—ovarian cancer	0.00013	0.000391	CcSEcCtD
Rabeprazole—Somnolence—Docetaxel—ovarian cancer	0.000129	0.00039	CcSEcCtD
Rabeprazole—Eye disorder—Epirubicin—ovarian cancer	0.000129	0.000389	CcSEcCtD
Rabeprazole—Tinnitus—Epirubicin—ovarian cancer	0.000129	0.000388	CcSEcCtD
Rabeprazole—Rhinitis—Doxorubicin—ovarian cancer	0.000128	0.000386	CcSEcCtD
Rabeprazole—Dyspepsia—Docetaxel—ovarian cancer	0.000128	0.000386	CcSEcCtD
Rabeprazole—Hepatitis—Doxorubicin—ovarian cancer	0.000128	0.000385	CcSEcCtD
Rabeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000127	0.00271	CbGpPWpGaD
Rabeprazole—Pharyngitis—Doxorubicin—ovarian cancer	0.000127	0.000383	CcSEcCtD
Rabeprazole—Decreased appetite—Docetaxel—ovarian cancer	0.000126	0.000381	CcSEcCtD
Rabeprazole—Hypersensitivity—Paclitaxel—ovarian cancer	0.000126	0.000381	CcSEcCtD
Rabeprazole—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000126	0.000381	CcSEcCtD
Rabeprazole—Oedema peripheral—Doxorubicin—ovarian cancer	0.000126	0.00038	CcSEcCtD
Rabeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000126	0.00269	CbGpPWpGaD
Rabeprazole—Angiopathy—Epirubicin—ovarian cancer	0.000125	0.000378	CcSEcCtD
Rabeprazole—Urethral disorder—Doxorubicin—ovarian cancer	0.000125	0.000378	CcSEcCtD
Rabeprazole—Pain—Docetaxel—ovarian cancer	0.000124	0.000375	CcSEcCtD
Rabeprazole—Constipation—Docetaxel—ovarian cancer	0.000124	0.000375	CcSEcCtD
Rabeprazole—Chills—Epirubicin—ovarian cancer	0.000124	0.000374	CcSEcCtD
Rabeprazole—Arrhythmia—Epirubicin—ovarian cancer	0.000123	0.000372	CcSEcCtD
Rabeprazole—Visual impairment—Doxorubicin—ovarian cancer	0.000123	0.000371	CcSEcCtD
Rabeprazole—Asthenia—Paclitaxel—ovarian cancer	0.000123	0.000371	CcSEcCtD
Rabeprazole—Alopecia—Epirubicin—ovarian cancer	0.000122	0.000368	CcSEcCtD
Rabeprazole—Pruritus—Paclitaxel—ovarian cancer	0.000121	0.000366	CcSEcCtD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TP53—ovarian cancer	0.000121	0.00259	CbGpPWpGaD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000121	0.00259	CbGpPWpGaD
Rabeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000121	0.00258	CbGpPWpGaD
Rabeprazole—Erythema multiforme—Doxorubicin—ovarian cancer	0.000121	0.000364	CcSEcCtD
Rabeprazole—Erythema—Epirubicin—ovarian cancer	0.00012	0.000363	CcSEcCtD
Rabeprazole—Malnutrition—Epirubicin—ovarian cancer	0.00012	0.000363	CcSEcCtD
Rabeprazole—Feeling abnormal—Docetaxel—ovarian cancer	0.00012	0.000362	CcSEcCtD
Rabeprazole—Eye disorder—Doxorubicin—ovarian cancer	0.000119	0.00036	CcSEcCtD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000119	0.00255	CbGpPWpGaD
Rabeprazole—Tinnitus—Doxorubicin—ovarian cancer	0.000119	0.000359	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000119	0.000359	CcSEcCtD
Rabeprazole—Flatulence—Epirubicin—ovarian cancer	0.000118	0.000357	CcSEcCtD
Rabeprazole—Tension—Epirubicin—ovarian cancer	0.000118	0.000356	CcSEcCtD
Rabeprazole—Dysgeusia—Epirubicin—ovarian cancer	0.000118	0.000355	CcSEcCtD
Rabeprazole—Diarrhoea—Paclitaxel—ovarian cancer	0.000117	0.000354	CcSEcCtD
Rabeprazole—Nervousness—Epirubicin—ovarian cancer	0.000117	0.000352	CcSEcCtD
Rabeprazole—Back pain—Epirubicin—ovarian cancer	0.000116	0.000351	CcSEcCtD
Rabeprazole—Angiopathy—Doxorubicin—ovarian cancer	0.000116	0.00035	CcSEcCtD
Rabeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000116	0.00247	CbGpPWpGaD
Rabeprazole—Muscle spasms—Epirubicin—ovarian cancer	0.000116	0.000349	CcSEcCtD
Rabeprazole—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000115	0.00247	CbGpPWpGaD
Rabeprazole—Abdominal pain—Docetaxel—ovarian cancer	0.000115	0.000347	CcSEcCtD
Rabeprazole—Body temperature increased—Docetaxel—ovarian cancer	0.000115	0.000347	CcSEcCtD
Rabeprazole—Chills—Doxorubicin—ovarian cancer	0.000115	0.000346	CcSEcCtD
Rabeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000115	0.00245	CbGpPWpGaD
Rabeprazole—Arrhythmia—Doxorubicin—ovarian cancer	0.000114	0.000344	CcSEcCtD
Rabeprazole—Dizziness—Paclitaxel—ovarian cancer	0.000113	0.000342	CcSEcCtD
Rabeprazole—Vision blurred—Epirubicin—ovarian cancer	0.000113	0.000342	CcSEcCtD
Rabeprazole—Alopecia—Doxorubicin—ovarian cancer	0.000113	0.000341	CcSEcCtD
Rabeprazole—Ill-defined disorder—Epirubicin—ovarian cancer	0.000112	0.000337	CcSEcCtD
Rabeprazole—Erythema—Doxorubicin—ovarian cancer	0.000111	0.000336	CcSEcCtD
Rabeprazole—Malnutrition—Doxorubicin—ovarian cancer	0.000111	0.000336	CcSEcCtD
Rabeprazole—Anaemia—Epirubicin—ovarian cancer	0.000111	0.000335	CcSEcCtD
Rabeprazole—Agitation—Epirubicin—ovarian cancer	0.00011	0.000333	CcSEcCtD
Rabeprazole—Flatulence—Doxorubicin—ovarian cancer	0.00011	0.000331	CcSEcCtD
Rabeprazole—Tension—Doxorubicin—ovarian cancer	0.000109	0.000329	CcSEcCtD
Rabeprazole—Vomiting—Paclitaxel—ovarian cancer	0.000109	0.000329	CcSEcCtD
Rabeprazole—Dysgeusia—Doxorubicin—ovarian cancer	0.000109	0.000329	CcSEcCtD
Rabeprazole—Malaise—Epirubicin—ovarian cancer	0.000108	0.000327	CcSEcCtD
Rabeprazole—Rash—Paclitaxel—ovarian cancer	0.000108	0.000326	CcSEcCtD
Rabeprazole—Dermatitis—Paclitaxel—ovarian cancer	0.000108	0.000326	CcSEcCtD
Rabeprazole—Nervousness—Doxorubicin—ovarian cancer	0.000108	0.000326	CcSEcCtD
Rabeprazole—Vertigo—Epirubicin—ovarian cancer	0.000108	0.000326	CcSEcCtD
Rabeprazole—Syncope—Epirubicin—ovarian cancer	0.000108	0.000325	CcSEcCtD
Rabeprazole—Leukopenia—Epirubicin—ovarian cancer	0.000108	0.000325	CcSEcCtD
Rabeprazole—Back pain—Doxorubicin—ovarian cancer	0.000108	0.000325	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	0.000108	0.0023	CbGpPWpGaD
Rabeprazole—Headache—Paclitaxel—ovarian cancer	0.000108	0.000324	CcSEcCtD
Rabeprazole—Hypersensitivity—Docetaxel—ovarian cancer	0.000107	0.000323	CcSEcCtD
Rabeprazole—Muscle spasms—Doxorubicin—ovarian cancer	0.000107	0.000323	CcSEcCtD
Rabeprazole—Palpitations—Epirubicin—ovarian cancer	0.000106	0.000321	CcSEcCtD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	0.000106	0.00227	CbGpPWpGaD
Rabeprazole—Loss of consciousness—Epirubicin—ovarian cancer	0.000106	0.000319	CcSEcCtD
Rabeprazole—Cough—Epirubicin—ovarian cancer	0.000105	0.000316	CcSEcCtD
Rabeprazole—Vision blurred—Doxorubicin—ovarian cancer	0.000105	0.000316	CcSEcCtD
Rabeprazole—Asthenia—Docetaxel—ovarian cancer	0.000104	0.000315	CcSEcCtD
Rabeprazole—Convulsion—Epirubicin—ovarian cancer	0.000104	0.000314	CcSEcCtD
Rabeprazole—Hypertension—Epirubicin—ovarian cancer	0.000104	0.000313	CcSEcCtD
Rabeprazole—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000103	0.000311	CcSEcCtD
Rabeprazole—Pruritus—Docetaxel—ovarian cancer	0.000103	0.00031	CcSEcCtD
Rabeprazole—Anaemia—Doxorubicin—ovarian cancer	0.000103	0.00031	CcSEcCtD
Rabeprazole—Arthralgia—Epirubicin—ovarian cancer	0.000102	0.000309	CcSEcCtD
Rabeprazole—Myalgia—Epirubicin—ovarian cancer	0.000102	0.000309	CcSEcCtD
Rabeprazole—Chest pain—Epirubicin—ovarian cancer	0.000102	0.000309	CcSEcCtD
Rabeprazole—Agitation—Doxorubicin—ovarian cancer	0.000102	0.000308	CcSEcCtD
Rabeprazole—Anxiety—Epirubicin—ovarian cancer	0.000102	0.000308	CcSEcCtD
Rabeprazole—Nausea—Paclitaxel—ovarian cancer	0.000102	0.000308	CcSEcCtD
Rabeprazole—Discomfort—Epirubicin—ovarian cancer	0.000101	0.000305	CcSEcCtD
Rabeprazole—Malaise—Doxorubicin—ovarian cancer	0.0001	0.000303	CcSEcCtD
Rabeprazole—Dry mouth—Epirubicin—ovarian cancer	0.0001	0.000302	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.0001	0.00214	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.0001	0.00214	CbGpPWpGaD
Rabeprazole—Vertigo—Doxorubicin—ovarian cancer	9.99e-05	0.000301	CcSEcCtD
Rabeprazole—Syncope—Doxorubicin—ovarian cancer	9.98e-05	0.000301	CcSEcCtD
Rabeprazole—Leukopenia—Doxorubicin—ovarian cancer	9.96e-05	0.0003	CcSEcCtD
Rabeprazole—Diarrhoea—Docetaxel—ovarian cancer	9.95e-05	0.0003	CcSEcCtD
Rabeprazole—Confusional state—Epirubicin—ovarian cancer	9.89e-05	0.000298	CcSEcCtD
Rabeprazole—Palpitations—Doxorubicin—ovarian cancer	9.83e-05	0.000297	CcSEcCtD
Rabeprazole—Anaphylactic shock—Epirubicin—ovarian cancer	9.81e-05	0.000296	CcSEcCtD
Rabeprazole—Oedema—Epirubicin—ovarian cancer	9.81e-05	0.000296	CcSEcCtD
Rabeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	9.8e-05	0.00209	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	9.79e-05	0.00209	CbGpPWpGaD
Rabeprazole—Loss of consciousness—Doxorubicin—ovarian cancer	9.78e-05	0.000295	CcSEcCtD
Rabeprazole—Cough—Doxorubicin—ovarian cancer	9.71e-05	0.000293	CcSEcCtD
Rabeprazole—Shock—Epirubicin—ovarian cancer	9.65e-05	0.000291	CcSEcCtD
Rabeprazole—Convulsion—Doxorubicin—ovarian cancer	9.64e-05	0.000291	CcSEcCtD
Rabeprazole—Dizziness—Docetaxel—ovarian cancer	9.62e-05	0.00029	CcSEcCtD
Rabeprazole—Thrombocytopenia—Epirubicin—ovarian cancer	9.61e-05	0.00029	CcSEcCtD
Rabeprazole—Hypertension—Doxorubicin—ovarian cancer	9.6e-05	0.00029	CcSEcCtD
Rabeprazole—Tachycardia—Epirubicin—ovarian cancer	9.58e-05	0.000289	CcSEcCtD
Rabeprazole—Hyperhidrosis—Epirubicin—ovarian cancer	9.49e-05	0.000286	CcSEcCtD
Rabeprazole—Arthralgia—Doxorubicin—ovarian cancer	9.47e-05	0.000286	CcSEcCtD
Rabeprazole—Chest pain—Doxorubicin—ovarian cancer	9.47e-05	0.000286	CcSEcCtD
Rabeprazole—Myalgia—Doxorubicin—ovarian cancer	9.47e-05	0.000286	CcSEcCtD
Rabeprazole—Anxiety—Doxorubicin—ovarian cancer	9.44e-05	0.000285	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—AQP3—ovarian cancer	9.4e-05	0.00201	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	9.39e-05	0.00201	CbGpPWpGaD
Rabeprazole—Discomfort—Doxorubicin—ovarian cancer	9.36e-05	0.000282	CcSEcCtD
Rabeprazole—Anorexia—Epirubicin—ovarian cancer	9.35e-05	0.000282	CcSEcCtD
Rabeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	9.33e-05	0.00199	CbGpPWpGaD
Rabeprazole—Dry mouth—Doxorubicin—ovarian cancer	9.26e-05	0.000279	CcSEcCtD
Rabeprazole—Vomiting—Docetaxel—ovarian cancer	9.25e-05	0.000279	CcSEcCtD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	9.21e-05	0.00197	CbGpPWpGaD
Rabeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	9.2e-05	0.00197	CbGpPWpGaD
Rabeprazole—Rash—Docetaxel—ovarian cancer	9.17e-05	0.000277	CcSEcCtD
Rabeprazole—Hypotension—Epirubicin—ovarian cancer	9.17e-05	0.000277	CcSEcCtD
Rabeprazole—Dermatitis—Docetaxel—ovarian cancer	9.16e-05	0.000276	CcSEcCtD
Rabeprazole—Confusional state—Doxorubicin—ovarian cancer	9.15e-05	0.000276	CcSEcCtD
Rabeprazole—Headache—Docetaxel—ovarian cancer	9.11e-05	0.000275	CcSEcCtD
Rabeprazole—Anaphylactic shock—Doxorubicin—ovarian cancer	9.08e-05	0.000274	CcSEcCtD
Rabeprazole—Oedema—Doxorubicin—ovarian cancer	9.08e-05	0.000274	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	9.01e-05	0.00193	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Epirubicin—ovarian cancer	8.94e-05	0.00027	CcSEcCtD
Rabeprazole—Shock—Doxorubicin—ovarian cancer	8.93e-05	0.000269	CcSEcCtD
Rabeprazole—Thrombocytopenia—Doxorubicin—ovarian cancer	8.89e-05	0.000268	CcSEcCtD
Rabeprazole—Insomnia—Epirubicin—ovarian cancer	8.87e-05	0.000268	CcSEcCtD
Rabeprazole—Tachycardia—Doxorubicin—ovarian cancer	8.86e-05	0.000267	CcSEcCtD
Rabeprazole—Paraesthesia—Epirubicin—ovarian cancer	8.81e-05	0.000266	CcSEcCtD
Rabeprazole—Hyperhidrosis—Doxorubicin—ovarian cancer	8.78e-05	0.000265	CcSEcCtD
Rabeprazole—Dyspnoea—Epirubicin—ovarian cancer	8.75e-05	0.000264	CcSEcCtD
Rabeprazole—Somnolence—Epirubicin—ovarian cancer	8.72e-05	0.000263	CcSEcCtD
Rabeprazole—Anorexia—Doxorubicin—ovarian cancer	8.65e-05	0.000261	CcSEcCtD
Rabeprazole—Nausea—Docetaxel—ovarian cancer	8.64e-05	0.000261	CcSEcCtD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	8.64e-05	0.00185	CbGpPWpGaD
Rabeprazole—Dyspepsia—Epirubicin—ovarian cancer	8.64e-05	0.000261	CcSEcCtD
Rabeprazole—Decreased appetite—Epirubicin—ovarian cancer	8.53e-05	0.000257	CcSEcCtD
Rabeprazole—Hypotension—Doxorubicin—ovarian cancer	8.48e-05	0.000256	CcSEcCtD
Rabeprazole—Pain—Epirubicin—ovarian cancer	8.39e-05	0.000253	CcSEcCtD
Rabeprazole—Constipation—Epirubicin—ovarian cancer	8.39e-05	0.000253	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	8.32e-05	0.00178	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	8.27e-05	0.00025	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	8.22e-05	0.00176	CbGpPWpGaD
Rabeprazole—Insomnia—Doxorubicin—ovarian cancer	8.21e-05	0.000248	CcSEcCtD
Rabeprazole—CYP1A1—Biological oxidations—CYP1B1—ovarian cancer	8.16e-05	0.00174	CbGpPWpGaD
Rabeprazole—Paraesthesia—Doxorubicin—ovarian cancer	8.15e-05	0.000246	CcSEcCtD
Rabeprazole—Dyspnoea—Doxorubicin—ovarian cancer	8.09e-05	0.000244	CcSEcCtD
Rabeprazole—Feeling abnormal—Epirubicin—ovarian cancer	8.09e-05	0.000244	CcSEcCtD
Rabeprazole—Somnolence—Doxorubicin—ovarian cancer	8.07e-05	0.000243	CcSEcCtD
Rabeprazole—CYP1A1—Metapathway biotransformation—CYP1B1—ovarian cancer	8.05e-05	0.00172	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Epirubicin—ovarian cancer	8.02e-05	0.000242	CcSEcCtD
Rabeprazole—Dyspepsia—Doxorubicin—ovarian cancer	7.99e-05	0.000241	CcSEcCtD
Rabeprazole—Decreased appetite—Doxorubicin—ovarian cancer	7.89e-05	0.000238	CcSEcCtD
Rabeprazole—Urticaria—Epirubicin—ovarian cancer	7.8e-05	0.000235	CcSEcCtD
Rabeprazole—Pain—Doxorubicin—ovarian cancer	7.76e-05	0.000234	CcSEcCtD
Rabeprazole—Constipation—Doxorubicin—ovarian cancer	7.76e-05	0.000234	CcSEcCtD
Rabeprazole—Body temperature increased—Epirubicin—ovarian cancer	7.76e-05	0.000234	CcSEcCtD
Rabeprazole—Abdominal pain—Epirubicin—ovarian cancer	7.76e-05	0.000234	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	7.66e-05	0.00164	CbGpPWpGaD
Rabeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.56e-05	0.00162	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	7.49e-05	0.0016	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	7.49e-05	0.0016	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	7.49e-05	0.0016	CbGpPWpGaD
Rabeprazole—Feeling abnormal—Doxorubicin—ovarian cancer	7.48e-05	0.000226	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Doxorubicin—ovarian cancer	7.42e-05	0.000224	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—NME2—ovarian cancer	7.35e-05	0.00157	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Epirubicin—ovarian cancer	7.23e-05	0.000218	CcSEcCtD
Rabeprazole—Urticaria—Doxorubicin—ovarian cancer	7.21e-05	0.000218	CcSEcCtD
Rabeprazole—Abdominal pain—Doxorubicin—ovarian cancer	7.18e-05	0.000217	CcSEcCtD
Rabeprazole—Body temperature increased—Doxorubicin—ovarian cancer	7.18e-05	0.000217	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	7.13e-05	0.00152	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	7.07e-05	0.00151	CbGpPWpGaD
Rabeprazole—Asthenia—Epirubicin—ovarian cancer	7.04e-05	0.000212	CcSEcCtD
Rabeprazole—Pruritus—Epirubicin—ovarian cancer	6.94e-05	0.000209	CcSEcCtD
Rabeprazole—Diarrhoea—Epirubicin—ovarian cancer	6.71e-05	0.000203	CcSEcCtD
Rabeprazole—Hypersensitivity—Doxorubicin—ovarian cancer	6.69e-05	0.000202	CcSEcCtD
Rabeprazole—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	6.68e-05	0.00143	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	6.59e-05	0.00141	CbGpPWpGaD
Rabeprazole—Asthenia—Doxorubicin—ovarian cancer	6.51e-05	0.000196	CcSEcCtD
Rabeprazole—Dizziness—Epirubicin—ovarian cancer	6.49e-05	0.000196	CcSEcCtD
Rabeprazole—Pruritus—Doxorubicin—ovarian cancer	6.42e-05	0.000194	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	6.38e-05	0.00136	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	6.38e-05	0.00136	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.29e-05	0.00135	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	6.24e-05	0.00133	CbGpPWpGaD
Rabeprazole—Vomiting—Epirubicin—ovarian cancer	6.24e-05	0.000188	CcSEcCtD
Rabeprazole—Diarrhoea—Doxorubicin—ovarian cancer	6.21e-05	0.000187	CcSEcCtD
Rabeprazole—Rash—Epirubicin—ovarian cancer	6.19e-05	0.000187	CcSEcCtD
Rabeprazole—Dermatitis—Epirubicin—ovarian cancer	6.18e-05	0.000186	CcSEcCtD
Rabeprazole—Headache—Epirubicin—ovarian cancer	6.15e-05	0.000185	CcSEcCtD
Rabeprazole—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	6.14e-05	0.00131	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	6.09e-05	0.0013	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	6.06e-05	0.00129	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	6.01e-05	0.00129	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	6.01e-05	0.00128	CbGpPWpGaD
Rabeprazole—Dizziness—Doxorubicin—ovarian cancer	6e-05	0.000181	CcSEcCtD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	5.88e-05	0.00126	CbGpPWpGaD
Rabeprazole—Nausea—Epirubicin—ovarian cancer	5.83e-05	0.000176	CcSEcCtD
Rabeprazole—Vomiting—Doxorubicin—ovarian cancer	5.77e-05	0.000174	CcSEcCtD
Rabeprazole—Rash—Doxorubicin—ovarian cancer	5.72e-05	0.000173	CcSEcCtD
Rabeprazole—Dermatitis—Doxorubicin—ovarian cancer	5.72e-05	0.000173	CcSEcCtD
Rabeprazole—Headache—Doxorubicin—ovarian cancer	5.69e-05	0.000172	CcSEcCtD
Rabeprazole—Nausea—Doxorubicin—ovarian cancer	5.39e-05	0.000163	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	5.31e-05	0.00113	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	5.24e-05	0.00112	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	5.2e-05	0.00111	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.15e-05	0.0011	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	5.13e-05	0.0011	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NME2—ovarian cancer	4.98e-05	0.00106	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	4.88e-05	0.00104	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	4.78e-05	0.00102	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	4.78e-05	0.00102	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	4.78e-05	0.00102	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.75e-05	0.00102	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYTB—ovarian cancer	4.74e-05	0.00101	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.7e-05	0.001	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.59e-05	0.000981	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	4.51e-05	0.000964	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.22e-05	0.000902	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PPP1CC—ovarian cancer	4.14e-05	0.000885	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—BRIP1—ovarian cancer	4.14e-05	0.000885	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NME2—ovarian cancer	4.07e-05	0.00087	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	4.02e-05	0.000858	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.01e-05	0.000858	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.96e-05	0.000847	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	3.83e-05	0.00082	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NME2—ovarian cancer	3.75e-05	0.0008	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NME2—ovarian cancer	3.71e-05	0.000794	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.63e-05	0.000775	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.45e-05	0.000738	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.44e-05	0.000735	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYTB—ovarian cancer	3.21e-05	0.000685	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NME2—ovarian cancer	3.17e-05	0.000678	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.15e-05	0.000673	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.13e-05	0.00067	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.82e-05	0.000602	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.8e-05	0.000599	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.8e-05	0.000599	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—YAP1—ovarian cancer	2.78e-05	0.000594	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.69e-05	0.000575	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYTB—ovarian cancer	2.62e-05	0.000561	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.57e-05	0.000549	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.56e-05	0.000548	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NME2—ovarian cancer	2.45e-05	0.000523	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYTB—ovarian cancer	2.41e-05	0.000516	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYTB—ovarian cancer	2.39e-05	0.000511	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.34e-05	0.0005	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—BRIP1—ovarian cancer	2.29e-05	0.00049	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PPP1CC—ovarian cancer	2.29e-05	0.00049	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—FASN—ovarian cancer	2.26e-05	0.000484	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—SLC5A5—ovarian cancer	2.23e-05	0.000476	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.19e-05	0.000469	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—SLC2A1—ovarian cancer	2.15e-05	0.00046	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.11e-05	0.000451	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.11e-05	0.000451	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.09e-05	0.000447	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.09e-05	0.000447	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP1B1—ovarian cancer	2.06e-05	0.000441	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYTB—ovarian cancer	2.04e-05	0.000437	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.04e-05	0.000437	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2e-05	0.000427	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—YAP1—ovarian cancer	1.88e-05	0.000402	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.86e-05	0.000398	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PPP2R1A—ovarian cancer	1.83e-05	0.000391	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.79e-05	0.000382	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.79e-05	0.000382	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—ABCB1—ovarian cancer	1.7e-05	0.000363	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.67e-05	0.000357	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—TYMS—ovarian cancer	1.67e-05	0.000356	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.64e-05	0.00035	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYTB—ovarian cancer	1.58e-05	0.000337	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—YAP1—ovarian cancer	1.54e-05	0.000329	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—FASN—ovarian cancer	1.53e-05	0.000328	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.52e-05	0.000326	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.52e-05	0.000325	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.51e-05	0.000322	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.46e-05	0.000311	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.43e-05	0.000305	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—YAP1—ovarian cancer	1.41e-05	0.000302	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—YAP1—ovarian cancer	1.4e-05	0.0003	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.4e-05	0.000298	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.39e-05	0.000297	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.38e-05	0.000295	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.38e-05	0.000295	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CAV1—ovarian cancer	1.34e-05	0.000287	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.34e-05	0.000286	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.3e-05	0.000278	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—FASN—ovarian cancer	1.25e-05	0.000268	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	1.24e-05	0.000265	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.23e-05	0.000264	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.23e-05	0.000263	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CG—ovarian cancer	1.22e-05	0.000262	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.22e-05	0.000261	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—YAP1—ovarian cancer	1.2e-05	0.000256	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.19e-05	0.000255	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.19e-05	0.000254	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.17e-05	0.000249	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—FASN—ovarian cancer	1.15e-05	0.000247	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—ABCB1—ovarian cancer	1.15e-05	0.000246	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—FASN—ovarian cancer	1.14e-05	0.000244	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.14e-05	0.000244	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.13e-05	0.000242	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—TYMS—ovarian cancer	1.13e-05	0.000241	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.12e-05	0.00024	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.1e-05	0.000234	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.09e-05	0.000232	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CD—ovarian cancer	1.08e-05	0.00023	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.06e-05	0.000227	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.05e-05	0.000225	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.04e-05	0.000223	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.04e-05	0.000223	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.01e-05	0.000217	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.01e-05	0.000215	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—FASN—ovarian cancer	9.77e-06	0.000209	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—SLC5A5—ovarian cancer	9.61e-06	0.000205	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—ABCB1—ovarian cancer	9.41e-06	0.000201	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CB—ovarian cancer	9.38e-06	0.0002	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.32e-06	0.000199	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—SLC2A1—ovarian cancer	9.28e-06	0.000198	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—YAP1—ovarian cancer	9.25e-06	0.000198	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—TYMS—ovarian cancer	9.24e-06	0.000197	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	9.24e-06	0.000197	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.19e-06	0.000196	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CAV1—ovarian cancer	9.1e-06	0.000194	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.09e-06	0.000194	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP1B1—ovarian cancer	8.9e-06	0.00019	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.69e-06	0.000186	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.65e-06	0.000185	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—ABCB1—ovarian cancer	8.58e-06	0.000183	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—TYMS—ovarian cancer	8.5e-06	0.000182	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—TYMS—ovarian cancer	8.42e-06	0.00018	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CG—ovarian cancer	8.28e-06	0.000177	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTEN—ovarian cancer	8.1e-06	0.000173	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	7.89e-06	0.000169	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.85e-06	0.000168	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—FASN—ovarian cancer	7.54e-06	0.000161	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CAV1—ovarian cancer	7.44e-06	0.000159	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.42e-06	0.000159	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—ABCB1—ovarian cancer	7.33e-06	0.000157	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CD—ovarian cancer	7.28e-06	0.000156	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—TYMS—ovarian cancer	7.2e-06	0.000154	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.16e-06	0.000153	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.11e-06	0.000152	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.87e-06	0.000147	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CAV1—ovarian cancer	6.85e-06	0.000146	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CAV1—ovarian cancer	6.79e-06	0.000145	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CG—ovarian cancer	6.78e-06	0.000145	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.48e-06	0.000139	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CB—ovarian cancer	6.35e-06	0.000136	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.24e-06	0.000133	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.18e-06	0.000132	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.09e-06	0.00013	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CD—ovarian cancer	5.96e-06	0.000127	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CAV1—ovarian cancer	5.8e-06	0.000124	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CA—ovarian cancer	5.72e-06	0.000122	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.66e-06	0.000121	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—TYMS—ovarian cancer	5.55e-06	0.000119	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.54e-06	0.000118	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTEN—ovarian cancer	5.49e-06	0.000117	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.48e-06	0.000117	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.43e-06	0.000116	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CG—ovarian cancer	5.28e-06	0.000113	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CB—ovarian cancer	5.19e-06	0.000111	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.78e-06	0.000102	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.74e-06	0.000101	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—AKT1—ovarian cancer	4.67e-06	9.98e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CD—ovarian cancer	4.64e-06	9.93e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTEN—ovarian cancer	4.49e-06	9.59e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CAV1—ovarian cancer	4.48e-06	9.57e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTEN—ovarian cancer	4.13e-06	8.83e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTEN—ovarian cancer	4.09e-06	8.75e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.08e-06	8.71e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.05e-06	8.65e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CA—ovarian cancer	3.87e-06	8.27e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.58e-06	7.66e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTEN—ovarian cancer	3.5e-06	7.48e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CA—ovarian cancer	3.17e-06	6.77e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—AKT1—ovarian cancer	3.16e-06	6.76e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.12e-06	6.68e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.91e-06	6.23e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.89e-06	6.17e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTEN—ovarian cancer	2.7e-06	5.77e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—AKT1—ovarian cancer	2.59e-06	5.53e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.47e-06	5.27e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—AKT1—ovarian cancer	2.38e-06	5.09e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—AKT1—ovarian cancer	2.36e-06	5.04e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—AKT1—ovarian cancer	2.02e-06	4.31e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.9e-06	4.07e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—AKT1—ovarian cancer	1.56e-06	3.33e-05	CbGpPWpGaD
